<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710385</url>
  </required_header>
  <id_info>
    <org_study_id>5518</org_study_id>
    <nct_id>NCT00710385</nct_id>
  </id_info>
  <brief_title>Abuse Liability of Suboxone Versus Subutex</brief_title>
  <official_title>Reinforcing Effects of Intravenous Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intravenous Drug Users (P05207)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to compare the abuse liabilities of intravenous buprenorphine and
      buprenorphine/naloxone in individuals who are physically dependent on sublingual
      buprenorphine. We hypothesize that the abuse liability of buprenorphine/naloxone is lower
      than that of buprenorphine alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Drug dependence is a major international public health problem of which opioid dependence,
      notably involving heroin, is a major component. Opioid dependence affects an estimated 13
      million injection drug users (IDUs) worldwide. The high health service costs for the
      treatment of diseases related to non-medical drug use and the high cost to society of
      drug-related behavior have prompted researchers to seek new medications and treatment
      strategies for opioid dependence. Buprenorphine, a mu-opiate receptor partial agonist and
      kappa-opiate receptor antagonist, is one such new medication that has had a significant role
      in expanding access to effective opioid dependence treatment. It is available as Subutex
      (buprenorphine alone) or Suboxone (a combination of buprenorphine and naloxone). Although it
      is commonly believed that the abuse potential of buprenorphine is low, numerous countries
      have reported illicit diversion of buprenorphine and a growing population of buprenorphine
      abusers. Theoretically, Suboxone would have lower abuse potential. When used sublingually, as
      prescribed, the amount of naloxone absorbed is negligible. However, if a patient crushes the
      tablet and attempts to inject or sniff the medication, the naloxone will become effective as
      an opioid antagonist and may precipitate withdrawal signs and symptoms in individuals
      dependent on full opioid agonists and/or attenuate the euphoric effects of the buprenorphine
      that is also contained in the medication. To date, few laboratory studies have evaluated the
      abuse liability of buprenorphine in humans using a drug self-administration protocol. We are
      proposing to evaluate the abuse potential of intravenous (IV) buprenorphine compared to IV
      buprenorphine/naloxone in buprenorphine-maintained injection drug users (IDUs), incorporating
      self-administration procedures with other measures of opioid effects. The proposed study will
      investigate the conditions that affect the self-administration of IV buprenorphine by
      buprenorphine abusers. The primary aim of the study is to compare the reinforcing effects of
      IV buprenorphine and IV buprenorphine/naloxone in IDUs maintained on different doses of
      sublingual buprenorphine (2, 8, and 24 mg/day). Secondary aims of the study are to compare
      the subjective, performance and physiological effects of IV buprenorphine and IV
      buprenorphine/naloxone. IV-administered placebo (saline), naloxone alone, and heroin alone
      will be tested as neutral, negative, and positive control conditions, respectively.
      Participants (N=12 completers) will reside on an inpatient unit (the General Clinical
      Research Unit, GCRU) during a 7 to 8-week study. This research will provide useful
      information for clinicians treating opioid dependent individuals with buprenorphine, and
      importantly, will provide information about the abuse potential and effects of buprenorphine
      on multiple measures of human functioning.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug's Breakpoint</measure>
    <time_frame>Single measurement taken following each of the 7 IV experimental doses</time_frame>
    <description>Measure of a drug's reinforcing effects. The &quot;Breakpoint&quot; is the point at which the participant stop performing an operant task (clicks on a mouse) in order to received the drug. Therefore, the reported breakpoint is the total amount of work the participant was willing to perform to receive the dose being tested</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug &quot;Liking&quot;</measure>
    <time_frame>Peak (highest) rating obtained following drug administration throughout the entire 3 hr session</time_frame>
    <description>Participant's subjective ratings of how much they &quot;Like&quot; the dose they just received on a scale of 0 -100.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Opioid-related Disorders</condition>
  <arm_group>
    <arm_group_label>Heroin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Heroin 25 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naloxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naloxone (NAL) .4 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Bup Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined dosing groups of (4 mg and 8mg of Buprenorphine) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Bup/Nal Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined dosing groups of (4/1 mg and 8/2mg of Buprenorphine + Naloxone) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Bup Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined dosing groups of (8mg and 16mg of Bup) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Bup/Nal Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combined dosing groups of (8/2mg and 16/4mg of Buprenorphine + Naloxone) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous placebo (PCB) administration. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heroin</intervention_name>
    <description>Heroin (25 mg)</description>
    <arm_group_label>Heroin</arm_group_label>
    <other_name>Diacetylmorphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>.4 mg</description>
    <arm_group_label>Naloxone</arm_group_label>
    <other_name>Naloxone Hydrochloride (HCl)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Bup Dose</intervention_name>
    <description>4 and 8 mg</description>
    <arm_group_label>Low Bup Dose</arm_group_label>
    <other_name>Subutex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Bup Dose</intervention_name>
    <description>8mg and 16 mg</description>
    <arm_group_label>High Bup Dose</arm_group_label>
    <other_name>Subutex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low Bup/Nal Dose</intervention_name>
    <description>Buprenorphine/Naloxone 4/1 mg, 8/2 mg</description>
    <arm_group_label>Low Bup/Nal Dose</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High Bup/Nal Dose</intervention_name>
    <description>Buprenorphine/Naloxone 8/2 mg, 16/4 mg</description>
    <arm_group_label>High Bup/Nal Dose</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (PCB)</intervention_name>
    <description>Placebo control administration</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>0 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnostic and Statistical Manual (DSM) IV criteria for heroin dependence

          -  No major mood, psychotic, or anxiety disorder

          -  Physically healthy

          -  Able to perform study procedures

          -  21-45 years of age

          -  Normal body weight

          -  Current use of i.v. opioids in amounts and/or frequencies that meet or exceed those
             used in the proposed study (1-2 bags of heroin per occasion at least twice per day)

          -  Self-administer at least 4 mg i.v. buprenorphine above placebo levels during the dose
             run up phase

        Exclusion Criteria:

          -  DSM IV criteria for dependence on drugs other than opioids, nicotine or caffeine

          -  Participants requesting treatment

          -  Participants on parole or probation

          -  Pregnancy or lactation

          -  Birth, miscarriage or abortion within 6 months

          -  Current or recent history of significant violent behavior

          -  Current major Axis I psychopathology, other than opioid dependence (e.g., mood
             disorder with functional impairment or suicide risk, schizophrenia), that might
             interfere with ability to participate in the study

          -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 3 times the upper
             limit of normal

          -  Significant suicide risk

          -  Current chronic pain

          -  Sensitivity, allergy, or contraindication to opioids

          -  Current or recent (past 30 days) physical dependence on or treatment with methadone,
             buprenorphine, or the buprenorphine/naloxone combination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra D Comer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University/New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute/Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010 Apr;105(4):709-18. doi: 10.1111/j.1360-0443.2009.02843.x. Erratum in: Addiction. 2010 Jul;105(7):1332.</citation>
    <PMID>20403021</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>July 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2008</study_first_posted>
  <results_first_submitted>August 19, 2011</results_first_submitted>
  <results_first_submitted_qc>October 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 5, 2016</results_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Heroin</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data have been published in a peer-reviewed journal.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment dates: September 10, 2007 - August 13, 2008 Location: Medical clinic</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Intravenous Challenge Doses</title>
          <description>This study employs a within-subjects design, all participants experienced all 7 intravenous challenge doses. The challenge doses were administered under 3 sublingual buprenorphine maintenance conditions. The data presented were collapsed across the 3 sublingual groups.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17">19 participants signed consent for the study 2 withdrew before any study procedures were initiated.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not qualify</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Undisclosed back pain</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Undisclosed excessive methadone use</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Challenge Doses</title>
          <description>This study employs a within-subjects design, all participant experience all challenge doses.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>verbal report verified by ID</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.2" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug's Breakpoint</title>
        <description>Measure of a drug's reinforcing effects. The &quot;Breakpoint&quot; is the point at which the participant stop performing an operant task (clicks on a mouse) in order to received the drug. Therefore, the reported breakpoint is the total amount of work the participant was willing to perform to receive the dose being tested</description>
        <time_frame>Single measurement taken following each of the 7 IV experimental doses</time_frame>
        <population>Heroin users, not seeking treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Heroin</title>
            <description>Intravenous heroin 25 mg</description>
          </group>
          <group group_id="O2">
            <title>Naloxone</title>
            <description>Intravenous Naloxone HCl</description>
          </group>
          <group group_id="O3">
            <title>Low Bup Dose</title>
            <description>Lower doses of intravenous buprenorphine alone.</description>
          </group>
          <group group_id="O4">
            <title>High Bup Dose</title>
            <description>Higher doses of intravenous buprenorphine</description>
          </group>
          <group group_id="O5">
            <title>Lower Bup/Nal Dose</title>
            <description>Lower doses of intravenous buprenorphine + naloxone.</description>
          </group>
          <group group_id="O6">
            <title>High Bup/Nal Dose</title>
            <description>Higher doses of intravenous buprenorphine +naloxone</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Control intravenous placebo drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug's Breakpoint</title>
          <description>Measure of a drug's reinforcing effects. The &quot;Breakpoint&quot; is the point at which the participant stop performing an operant task (clicks on a mouse) in order to received the drug. Therefore, the reported breakpoint is the total amount of work the participant was willing to perform to receive the dose being tested</description>
          <population>Heroin users, not seeking treatment</population>
          <units>number of clicks on a mouse</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1200" spread="200"/>
                    <measurement group_id="O2" value="10" spread="10"/>
                    <measurement group_id="O3" value="1100" spread="180"/>
                    <measurement group_id="O4" value="1200" spread="190"/>
                    <measurement group_id="O5" value="300" spread="100"/>
                    <measurement group_id="O6" value="750" spread="175"/>
                    <measurement group_id="O7" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug &quot;Liking&quot;</title>
        <description>Participant's subjective ratings of how much they &quot;Like&quot; the dose they just received on a scale of 0 -100.</description>
        <time_frame>Peak (highest) rating obtained following drug administration throughout the entire 3 hr session</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Heroin</title>
            <description>Intravenous heroin 25 mg</description>
          </group>
          <group group_id="O2">
            <title>Naloxone</title>
            <description>Intravenous Naloxone HCl</description>
          </group>
          <group group_id="O3">
            <title>Low Bup Dose</title>
            <description>Lower doses of intravenous buprenorphine alone.</description>
          </group>
          <group group_id="O4">
            <title>High Bup Dose</title>
            <description>Higher doses of intravenous buprenorphine</description>
          </group>
          <group group_id="O5">
            <title>Lower Bup/Nal Dose</title>
            <description>Lower doses of intravenous buprenorphine + naloxone.</description>
          </group>
          <group group_id="O6">
            <title>High Bup/Nal Dose</title>
            <description>Higher doses of intravenous buprenorphine +naloxone</description>
          </group>
          <group group_id="O7">
            <title>Placebo</title>
            <description>Control intravenous placebo drug administration.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug &quot;Liking&quot;</title>
          <description>Participant's subjective ratings of how much they &quot;Like&quot; the dose they just received on a scale of 0 -100.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" spread="5"/>
                    <measurement group_id="O2" value="3" spread="2.7"/>
                    <measurement group_id="O3" value="29.8" spread="4"/>
                    <measurement group_id="O4" value="42.5" spread="5"/>
                    <measurement group_id="O5" value="10.5" spread="2.4"/>
                    <measurement group_id="O6" value="27" spread="4"/>
                    <measurement group_id="O7" value="1" spread=".6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed for daily throughout the study.</time_frame>
      <desc>An adverse event (AE) was defined as any symptom, sign, illness or experience that develops or worsens in severity during the course of the study. A serious adverse event is any AE that was: Fatal, Life-threatening, Required or prolonged inpatient stay, Resulted in persistent or significant disability or incapacity.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined for All Study Conditions</title>
          <description>This study employed a within-subjects design, all participants experienced all study conditions.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mild Opioid Withdrawal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The stringent criteria for enrollment, qualification and retention in this trial were highly selective for a certain subpopulation of opioid-dependent individuals.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sandra D. Comer</name_or_title>
      <organization>Substance Abuse</organization>
      <phone>646-774-6146</phone>
      <email>sdc10@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

